Objective:To investigate the feasibility of the combination of detecting hypermethylated secreted frizzled-related protein 1(SFRP1)and secreted frizzled-related protein 2(SFRP2)in feces as a panel of biomarkers for colorectal cancer(CRC)screening.Methods:Methylation-specific PCR(MSP)was performed to analyze methylation status of SFRP1 and SFRP2 in a blinded fashion in tumor tissues and in matched stool samples from 39 patients with primary CRC,34 patients with adenomas,17 patients with hyperplastic polyps and 20 endoscopically normal subjects as normal controls.Simultaneously we analyzed the correlation of hypermethylated SFRP1 and SFRP2 with the clinicopathological features of CRC.Results:Hypermethylated SFRP1 was detected in 92.3%,76.5%,47.1% of tissue samples and in 89.7%,64.7%,35.3% of matched fecal samples from CRC,adenoma and hyperplastic polyp,respectively.Hypermethylated SFRP2 was detected in 87.2%,67.6%,35.3% of tissue samples and in 82.1%,55.9%,29.4% of matched fecal samples from CRC,adenoma and hyperplastic polyp,respectively.Of these two genes,at least one hypermethylated was 94.9%,82.4%,52.9% in tissue samples and 92.3%,73.5%,47.1% in matched fecal samples from CRC,adenoma and hyperplastic polyp,respectively.In contrast,no hypermethylated SFRP1 and SFRP2 were detected in mucosa tissues of normal controls,only 2 cases of fecal samples was detected with hypermethylated SFRP1 and another 1 case was detected with hypermethylated SFRP2.Moreover,no significant associations were observed between hypermethylated SFRP1,SFRP2 and clinicopathological features of CRC.Conclusion:Hypermethylation of SFRP1 and SFRP2 in feces are novel epigenetic biomarkers of CRC and carried high potential for the remote detection of CRC as non-invasive screening method,and combined analysis of hypermethylated SFRP1 and SFRP2 in fecal could further increase the detection rate of CRC and premalignant lesions. Objective: To investigate the feasibility of the combination of detecting hypermethylated secreted frizzled-related protein 1 (SFRP1) and secreted frizzled-related protein 2 (SFRP2) in feces as a panel of biomarkers for colorectal cancer (CRC) screening. Methods: Methylation- specific PCR (MSP) was performed to analyze methylation status of SFRP1 and SFRP2 in a blinded fashion in tumor tissues and in matched stool samples from 39 patients with primary CRC, 34 patients with adenomas, 17 patients with hyperplastic polyps and 20 endoscopically normal subjects as Results: Hypermethylated SFRP1 was detected in 92.3%, 76.5%, 47.1% of tissue samples and in 89.7%, 64.7%, 35.3% of matched fecal samples from CRC, adenoma and hyperplastic polyp, respectively. Hypermethylated SFRP2 was detected in 87.2%, 67.6%, 35.3% of tissue samples and in 82.1%, 55.9%, 29.4% of matched fecal samples from CRC, adenoma and hyperplastic polyp, respectively. Of these two genes, at least one hypermethylated was 94.9%, 82.4%, 52.9% in tissue samples and 92.3%, 73.5%, 47.1% in matched fecal samples from CRC, adenoma and hyperplastic polyp, respectively.In contrast, no hypermethylated SFRP1 and SFRP2 were detected in mucosa tissues of normal controls, only 2 cases of fecal samples were detected with hypermethylated SFRP1 and another 1 case was detected with hypermethylated SFRP2.Moreover, no significant associations were observed between hypermethylated SFRP1, SFRP2 and clinicopathological features of CRC.Conclusion: Hypermethylation of SFRP1 and SFRP2 in feces are novel epigenetic biomarkers of CRC and carried high potential for the remote detection of CRC as non-invasive screening method, and combined analysis of hypermethylated SFRP1 and SFRP2 in fecal could further increase the detection rate of CRC and premalignant lesions.